Doxorubicin News and Research RSS Feed - Doxorubicin News and Research

Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.

In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.
Multifunctional nanocapsules could enhance drug delivery to specific disease sites

Multifunctional nanocapsules could enhance drug delivery to specific disease sites

A nanoparticle-based drug delivery system that can sense and respond to different conditions in the body, as well as to an externally applied magnetic field, could enhance doctors’ ability to target drugs to specific sites of disease. [More]
Nanoparticles shaped like rods and worms could effectively deliver drugs, research suggests

Nanoparticles shaped like rods and worms could effectively deliver drugs, research suggests

When it comes to delivering drugs, nanoparticles shaped like rods and worms are the best bet for making the daunting journey to the centre of a cell, new Australian research suggests. [More]
Researchers identify higher risk of early chemotherapy-related death in older patients with DLBCL

Researchers identify higher risk of early chemotherapy-related death in older patients with DLBCL

Although diffuse large B-cell lymphoma (DLBCL) is a curable disease in most patients aged 65 years or older, these patients are also at higher risk of chemotherapy-related death within the first 30 days of treatment. [More]
Edible ginger-derived nano-lipids could effectively deliver drugs for treating colon cancer

Edible ginger-derived nano-lipids could effectively deliver drugs for treating colon cancer

Edible ginger-derived nano-lipids created from a specific population of ginger nanoparticles show promise for effectively targeting and delivering chemotherapeutic drugs used to treat colon cancer, according to a study by researchers at the Institute for Biomedical Sciences at Georgia State University, the Atlanta Veterans Affairs Medical Center and Wenzhou Medical University and Southwest University in China. [More]
Nebivolol treatment may protect against antracycline-induced cardiotoxicity in breast cancer patients

Nebivolol treatment may protect against antracycline-induced cardiotoxicity in breast cancer patients

Nebivolol prevents anthracycline-induced cardiotoxicity, according to research presented at ESC Congress 2016 today by Professor Mirela Cleopatra Tomescu, a cardiologist at Victor Babes University of Medicine and Pharmacy, Timisoara, Romania. [More]
Researchers find promising new therapy for both pediatric and adult cancers

Researchers find promising new therapy for both pediatric and adult cancers

A study conducted at Nationwide Children's Hospital has found that a new chemotherapy is effective against both pediatric and adult cancers, and that it allows other chemotherapies to more readily reach their targets. [More]
Salmonella protein can reduce drug resistant molecule found in cancer cells

Salmonella protein can reduce drug resistant molecule found in cancer cells

A surprising result in an experiment on Salmonella bacteria has led to a discovery that may make drug resistant cancer cells more treatable by conventional chemotherapies. [More]
Adding new monoclonal antibody to chemotherapy improves survival in soft-tissue sarcoma patients

Adding new monoclonal antibody to chemotherapy improves survival in soft-tissue sarcoma patients

Adding a novel monoclonal antibody therapy to traditional chemotherapy increased median survival by nearly a year in patients with advanced sarcoma, a lethal soft-tissue cancer. [More]
Researchers propose new approach to target chemotherapy medications specifically to sarcomas

Researchers propose new approach to target chemotherapy medications specifically to sarcomas

Sarcoma is an aggressive form of cancer responsible for up to 20 percent of childhood cancers. Tumors often first appear in the extremities and the abdomen. Surgery is a primary treatment, but it often is combined with chemotherapy. [More]
Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

The targeted therapy everolimus may be safely combined with R-CHOP for new, untreated diffuse large B-cell lymphoma according to the results of a pilot study by Mayo Clinic researchers published in the Lancet Haematology. [More]
New drug-capture device can soak up chemotherapy drugs to limit toxicity

New drug-capture device can soak up chemotherapy drugs to limit toxicity

Doctors have a powerful arsenal of cancer-fighting chemotherapy drugs to choose from, though a key challenge is to better target these drugs to kill tumors while limiting their potentially harmful side effects. [More]
EAD therapy can shrink size of triple-negative breast cancer tumors in mice

EAD therapy can shrink size of triple-negative breast cancer tumors in mice

In a new study using mice and lab-grown human cells, a scientific team led by Johns Hopkins Kimmel Cancer Center researchers show how a triple-drug cocktail can shrink triple-negative breast cancers by killing off cancer cells and halting new tumor growth. [More]
New drug combination before surgery may improve outcomes in breast cancer patients

New drug combination before surgery may improve outcomes in breast cancer patients

Results from the I-SPY 2 trial show that giving patients with HER2-positive invasive breast cancer a combination of the drugs trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab. [More]
Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

Ludwig Cancer Research and the Cancer Research Institute have launched a Phase 1/2 clinical trial of combination immunotherapy for advanced ovarian cancer. The international, multicenter trial is led by George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne and Brad Monk, director of Gynecologic Oncology at St. Joseph's Hospital and Medical Center. [More]
Scientists successfully turn off misbehaving protein that fuels growth of triple-negative breast cancer

Scientists successfully turn off misbehaving protein that fuels growth of triple-negative breast cancer

Working with human breast cancer cells, a team of scientists from Ann & Robert H. Lurie Children's Hospital of Chicago have successfully turned off a misbehaving protein that fuels the growth of a particularly aggressive, drug-resistant form of the disease known as triple-negative breast cancer. [More]
Mount Sinai Hospital uses M1 LUMI Bead loaded with doxorubicin for liver cancer treatment

Mount Sinai Hospital uses M1 LUMI Bead loaded with doxorubicin for liver cancer treatment

An innovative cancer treatment made of luminescent chemotherapy-filled beads injected into tumors through the wrist is now available for patients with inoperable and difficult-to-treat liver cancer. [More]
New drug could transform treatment of metastatic triple negative breast cancer

New drug could transform treatment of metastatic triple negative breast cancer

A team of investigators from Houston Methodist Research Institute may have transformed the treatment of metastatic triple negative breast cancer by creating the first drug to successfully eliminate lung metastases in mice. [More]
CWRU researcher to customize tobacco mosaic virus to treat human cancers

CWRU researcher to customize tobacco mosaic virus to treat human cancers

A Case Western Reserve University researcher has been awarded more than $3 million in federal and foundation grants to turn common plant viruses into cancer sleuths and search-and-destroy emissaries. [More]
Neurosurgeons use laser probe to deliver chemotherapy drugs to patients with glioblastoma

Neurosurgeons use laser probe to deliver chemotherapy drugs to patients with glioblastoma

Using a laser probe, neurosurgeons at Washington University School of Medicine in St. Louis have opened the brain's protective cover, enabling them to deliver chemotherapy drugs to patients with a form of deadly brain cancer. [More]
Over-expression of heme oxygenase-1 enzyme protects the heart from doxorubicin damage

Over-expression of heme oxygenase-1 enzyme protects the heart from doxorubicin damage

Life-threatening heart damage is an adverse side effect of the cancer drug doxorubicin, damage that also limits the use of newer chemotherapeutic agents such as trastuzumab and imatinib. The ability to protect the heart from these side effects would benefit patients, including cancer survivors who are at risk of developing heart damage years later, and it also could allow safer use of these drugs at higher doses. [More]
Advertisement
Advertisement